Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Cited by 61 Publications

Nature, 2018, 559(7713):211-216

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 142(3):444-55

PubMed: 20691903 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )
Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )
Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvmO3VKSzVyPUCuNFA{OzhizszN	M1HFeHNCVkeURWK=
RS4-11	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW3TWM2OD1yLkCwOFA1KM7:TR?=	M1HhWXNCVkeURWK=
MFH-ino	NXzqXG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEC5PUDPxE1?	M4HXTnNCVkeURWK=
NTERA-S-cl-D1	NIH6S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[0elBNUUN3ME2wMlAyPDN2IN88US=>	NEX0VpBUSU6JUlXS
697	NXvWS4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PyT2lEPTB;MD6wNlQ4OSEQvF2=	NYLDbGdWW0GQR2LFVi=>
NALM-6	NGT2SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1H6cWlEPTB;MD6wNlU2OiEQvF2=	M2PiVHNCVkeURWK=
ES8	M3r5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HnbGlEPTB;MD6wOFYyOyEQvF2=	MoPpV2FPT1KHUh?=
HUTU-80	NVy5fo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TCVGlEPTB;MD6wOVI6QSEQvF2=	MUPTRW5IWkWU
MV-4-11	NILYN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1G1O2lEPTB;MD6wO\|c5OiEQvF2=	M{\VXHNCVkeURWK=
MONO-MAC-6	M3jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETOcnRKSzVyPUCuNFc5PzlizszN	MVnTRW5IWkWU
LC-2-ad	NEPjOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XZSGlEPTB;MD6wPFc5QSEQvF2=	NF;a[2VUSU6JUlXS
BL-41	M1fqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XpW2lEPTB;MD6xNFQ1PSEQvF2=	M2PGenNCVkeURWK=
A4-Fuk	NWK1TJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDtOpJKSzVyPUCuNVE2PjNizszN	MmTFV2FPT1KHUh?=
SW954	MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMUKyNlkh\|ryP	NX\tXZhuW0GQR2LFVi=>
BV-173	NHXYd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHwTWM2OD1yLkGyOlQyKM7:TR?=	M2Lo[nNCVkeURWK=
TE-11	M{jETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[0SmZIUUN3ME2wMlE1QTh{IN88US=>	NXzTNFN5W0GQR2LFVi=>
SK-UT-1	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofpTWM2OD1yLkG1PVY2KM7:TR?=	MlHHV2FPT1KHUh?=
SIG-M5	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljpTWM2OD1yLkG2O\|A4KM7:TR?=	MlfHV2FPT1KHUh?=
OCUB-M	NV7nN4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHHTWM2OD1yLkG2PVg{KM7:TR?=	NUX0fpJSW0GQR2LFVi=>
K052	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm4TWM2OD1yLkG5OFgh\|ryP	Mki5V2FPT1KHUh?=
VA-ES-BJ	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnTbYVKSzVyPUCuNlAxQDZizszN	MVPTRW5IWkWU
SW982	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7hdnFpUUN3ME2wMlIyOzhizszN	MlHyV2FPT1KHUh?=
LB647-SCLC	NVXOUlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7KeGE{UUN3ME2wMlIyPTJ\|IN88US=>	M4LyOHNCVkeURWK=
PSN1	NVTPclFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XUOWlEPTB;MD6yNlAzPiEQvF2=	M1;mS3NCVkeURWK=
BB30-HNC	M3G4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTrTWM2OD1yLkKyOVkyKM7:TR?=	NI[xSWZUSU6JUlXS
ST486	M1znd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXnR\|ZtUUN3ME2wMlI{ODh5IN88US=>	NYnr[lQ1W0GQR2LFVi=>
MOLT-4	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL0TWM2OD1yLkKzN\|M4KM7:TR?=	M2rscXNCVkeURWK=
EW-16	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMkO3Olgh\|ryP	NFqwUohUSU6JUlXS
KS-1	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe3PYk1UUN3ME2wMlI{Pzh3IN88US=>	NEfzUWFUSU6JUlXS
SR	NF;TRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDSTWM2OD1yLkK0OVY1KM7:TR?=	M3jmTXNCVkeURWK=
KM12	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMk[zOkDPxE1?	MVvTRW5IWkWU
EM-2	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPuPXQxUUN3ME2wMlI3PjRzIN88US=>	NUjNTXR{W0GQR2LFVi=>
MEG-01	NYjSToRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkftTWM2OD1yLkK3PFQ6KM7:TR?=	MWHTRW5IWkWU
NB13	M1PS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfhd5Q5UUN3ME2wMlI4QTh2IN88US=>	MXzTRW5IWkWU
RKO	NXfDfpFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwM{C4NVMh\|ryP	MWPTRW5IWkWU
CESS	NF7XZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwM{GzNlgh\|ryP	NGGyPJVUSU6JUlXS
EoL-1-cell	M{jlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXRTWM2OD1yLkOzOFU6KM7:TR?=	M3\y[3NCVkeURWK=
DOHH-2	MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml22TWM2OD1yLkOzO\|gyKM7:TR?=	NFfySm1USU6JUlXS
A388	NVzrZ2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nEVGlEPTB;MD6zOFA5PiEQvF2=	NHrCbmRUSU6JUlXS
LAMA-84	NUm2O5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3viWWlEPTB;MD6zOVE4QCEQvF2=	NXHS[GxwW0GQR2LFVi=>
IMR-5	NVvrUpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\OWGQzUUN3ME2wMlM2PTRizszN	NHHJUGRUSU6JUlXS
KARPAS-422	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3lSJg2UUN3ME2wMlM4Ojd{IN88US=>	NFOwRnFUSU6JUlXS
MRK-nu-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwM{ixN{DPxE1?	NFPwTXpUSU6JUlXS
BL-70	NFrlTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwM{i5O\|Qh\|ryP	NWDBZo9YW0GQR2LFVi=>
LXF-289	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;VVnRTUUN3ME2wMlQxPDB4IN88US=>	MoPxV2FPT1KHUh?=
RL95-2	NEjYeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTzSpRYUUN3ME2wMlQxPTZ5IN88US=>	MYTTRW5IWkWU
QIMR-WIL	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37jPWlEPTB;MD60NlY4PiEQvF2=	MnXBV2FPT1KHUh?=
K-562	M4[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\QWmlEPTB;MD60N\|Q4OiEQvF2=	NV7wbmYxW0GQR2LFVi=>
NCI-H510A	NGXBeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjVc3J5UUN3ME2wMlQ{QDJ\|IN88US=>	NUWydWlSW0GQR2LFVi=>
NCI-H524	NXv5S5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LvTWlEPTB;MD61NVE1PyEQvF2=	M4SwbHNCVkeURWK=
KE-37	M{\6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z3[GlEPTB;MD61NlExOiEQvF2=	MnLvV2FPT1KHUh?=
KP-N-YS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjITWM2OD1yLkW0N\|kzKM7:TR?=	M3HNWHNCVkeURWK=
LS-411N	NEnVRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nTUGlEPTB;MD61O\|c2OiEQvF2=	NX;OOW5CW0GQR2LFVi=>
CTV-1	M1HFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnO5TWM2OD1yLkW4O\|c{KM7:TR?=	Mn;kV2FPT1KHUh?=
NCI-SNU-16	NFv0UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfrTWM2OD1yLk[zOVcyKM7:TR?=	NIXxc4ZUSU6JUlXS
HT-144	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPQTWM2OD1yLk[zO\|k5KM7:TR?=	MWHTRW5IWkWU
NCI-H187	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPZTWM2OD1yLk[0NVMh\|ryP	NFXJNlRUSU6JUlXS
OCI-AML2	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmqxTWM2OD1yLk[0OFA{KM7:TR?=	NHfqWZZUSU6JUlXS
CCRF-CEM	M{nNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PETGlEPTB;MD62OVM1PiEQvF2=	MUHTRW5IWkWU
ONS-76	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\4NmZKSzVyPUCuOlY1PThizszN	M2PGTHNCVkeURWK=
IST-SL2	NUjHT2doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwN{G5PFIh\|ryP	M4Sxd3NCVkeURWK=
NB6	NH2zR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:2VXRRUUN3ME2wMlc4OjV2IN88US=>	MUfTRW5IWkWU
SK-PN-DW	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXW[XNKSzVyPUCuO\|kyPCEQvF2=	MVfTRW5IWkWU
HCC1599	NHPGNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLKTWM2OD1yLkiwPFc1KM7:TR?=	NYLjR5dKW0GQR2LFVi=>
MC116	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3zZ5hKSzVyPUCuPFUxOTFizszN	M4rKN3NCVkeURWK=
TE-15	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwOEWwPVgh\|ryP	NIf4ZlFUSU6JUlXS
HOP-62	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[2TWM2OD1yLki2N\|I6KM7:TR?=	NEj3Z2lUSU6JUlXS
TGBC24TKB	M{WzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwOE[zPFUh\|ryP	MWLTRW5IWkWU
HCE-4	NEjYfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHu1RXhKSzVyPUCuPFgxPjNizszN	MnXGV2FPT1KHUh?=
ALL-PO	NIfmfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjmS\|N7UUN3ME2wMlg5OTd3IN88US=>	MXHTRW5IWkWU
KGN	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7NTWM2OD1yLki5PVk2KM7:TR?=	Mnq0V2FPT1KHUh?=
ML-2	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIL6VllKSzVyPUCuPVAzPTlizszN	Mmm1V2FPT1KHUh?=
ES4	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkmxTWM2OD1yLkmxNVI5KM7:TR?=	NYfZOlVSW0GQR2LFVi=>
SF126	NUfhZ5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwOUS4NVkh\|ryP	MoH4V2FPT1KHUh?=
SK-N-DZ	NFzsSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrw[49KSzVyPUCuPVYyQDlizszN	M{XmV3NCVkeURWK=
HCC1187	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrGTWM2OD1zLkCwOVA2KM7:TR?=	MoPlV2FPT1KHUh?=
DU-4475	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PRbWlEPTB;MT6wNVc2PiEQvF2=	MVPTRW5IWkWU
NKM-1	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LkWmlEPTB;MT6wNlc4PSEQvF2=	MWjTRW5IWkWU
HL-60	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrlWmRvUUN3ME2xMlA3PTd2IN88US=>	MmCyV2FPT1KHUh?=
SBC-1	NXHibIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3Kd3lKSzVyPUGuNVI2PDJizszN	NVr5ZYVpW0GQR2LFVi=>
TE-10	NVfpNmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTFwMUK5OFYh\|ryP	NWrEc2RkW0GQR2LFVi=>
ETK-1	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwMUO2NVMh\|ryP	M1vGdnNCVkeURWK=
HAL-01	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTyOllnUUN3ME2xMlE3PzB7IN88US=>	MYrTRW5IWkWU
BB65-RCC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXxO3piUUN3ME2xMlE5ODB3IN88US=>	NYTJOmw1W0GQR2LFVi=>
EW-1	NYXIXZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DEZ2lEPTB;MT6xPFU3OiEQvF2=	NYrZdWlTW0GQR2LFVi=>
SK-NEP-1	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTr[FZKSzVyPUGuNlEyOTFizszN	MnzRV2FPT1KHUh?=
SK-LMS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnvVIFUUUN3ME2xMlIzOjF{IN88US=>	MXHTRW5IWkWU
DEL	NYTCWlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTFwMkW2OFMh\|ryP	NYn1UWtTW0GQR2LFVi=>
GT3TKB	NXzJfG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1njVmlEPTB;MT6yPFA2PyEQvF2=	NHzKW\|NUSU6JUlXS
MOLT-16	NWHkN3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYThUYhXUUN3ME2xMlM2PDB3IN88US=>	NIi5N3FUSU6JUlXS
CMK	M4rUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7kfo5KSzVyPUGuOFIyOTdizszN	NXjZUlc5W0GQR2LFVi=>
NB5	NWX1ZWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\sXnQ2UUN3ME2xMlY1OjJ7IN88US=>	MXTTRW5IWkWU
NCI-H1963	M17zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;GTplRUUN3ME2xMlcxPTh\|IN88US=>	NED4SmtUSU6JUlXS
KURAMOCHI	NHnPTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPIU4lKSzVyPUGuO\|g6OTFizszN	MoHBV2FPT1KHUh?=
TE-8	NEn0WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoCwTWM2OD1zLkiwN\|Y5KM7:TR?=	Moj2V2FPT1KHUh?=
NCI-H1304	M{L6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1XWlEPTB;MT64N\|A4OyEQvF2=	M4jhenNCVkeURWK=
A101D	NEDxXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q3SWlEPTB;MT64O\|M6PSEQvF2=	NYO3To1FW0GQR2LFVi=>
SCLC-21H	NWPsNodRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLJTWM2OD1zLkm3NFU4KM7:TR?=	NFS3N2JUSU6JUlXS
GB-1	NIjRRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJwMEG2OFch\|ryP	NHzhdYFUSU6JUlXS
KARPAS-45	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJwMEK2OVQh\|ryP	NG\ObmJUSU6JUlXS
ATN-1	NFfZNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVu1V2V2UUN3ME2yMlAzQDV6IN88US=>	MUfTRW5IWkWU
NCI-H720	M160UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjVSoVkUUN3ME2yMlA3OjR2IN88US=>	NYTXd\|lzW0GQR2LFVi=>
RPMI-6666	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfVTWM2OD1{LkG2NlA4KM7:TR?=	MYnTRW5IWkWU
NB17	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfXTWM2OD1{LkK5Nlch\|ryP	MVLTRW5IWkWU
IST-SL1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jzbGlEPTB;Mj6yPVc3PSEQvF2=	NEHaenhUSU6JUlXS
SH-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33o[GlEPTB;Mj6zNlQ3QSEQvF2=	MUTTRW5IWkWU
K5	M3;0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TXfmlEPTB;Mj60NFMyQSEQvF2=	MUTTRW5IWkWU
OVCAR-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HBXGlEPTB;Mj60OlE{KM7:TR?=	MkDuV2FPT1KHUh?=
ACN	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJwNUCyNVMh\|ryP	MWfTRW5IWkWU
TGW	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;NR2lEPTB;Mj62OVg{OiEQvF2=	NXHIUmNpW0GQR2LFVi=>
NCI-H2107	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInkVlFKSzVyPUKuPFM4OTFizszN	NE\GSo1USU6JUlXS
NCI-H82	M4rqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XsU2lEPTB;Mj64N\|g{QCEQvF2=	MYHTRW5IWkWU
SK-N-FI	NEL0W\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz4TVFKSzVyPUKuPFY5PjhizszN	MYjTRW5IWkWU
LB1047-RCC	M2i1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTJwOEixNlYh\|ryP	NVrs[5FGW0GQR2LFVi=>
LU-134-A	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Huc2lEPTB;Mj64PVI3KM7:TR?=	M2\5OnNCVkeURWK=
NCI-H209	M2jhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjmNm1uUUN3ME2yMlkyOjV\|IN88US=>	MXrTRW5IWkWU
NOMO-1	NV62WHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nWXWlEPTB;Mz6wNlI4PCEQvF2=	NIDUXWdUSU6JUlXS
RH-1	M1LBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{ToOmlEPTB;Mz6xO\|I6OSEQvF2=	MX\TRW5IWkWU
LOUCY	NWO3NG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;0R3FYUUN3ME2zMlE5Pjl\|IN88US=>	M2D4VnNCVkeURWK=
TE-9	NWPWeFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7nTWM2OD1\|LkK2O\|M3KM7:TR?=	NXWzVmN3W0GQR2LFVi=>
PF-382	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki0TWM2OD1\|LkO1O\|c5KM7:TR?=	M4rMWnNCVkeURWK=
RPMI-8402	MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3PTWM2OD1\|LkW4OlA{KM7:TR?=	MWHTRW5IWkWU
HEL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTDXZc5UUN3ME2zMlY{OiEQvF2=	MXXTRW5IWkWU
NOS-1	NFvLe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTNwOES3OVQh\|ryP	NFnKTnhUSU6JUlXS
ES1	NHnBZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTNwOUKyPVMh\|ryP	MlLHV2FPT1KHUh?=
NCI-H2171	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjKT\|hyUUN3ME2zMlkzPDJ\|IN88US=>	M{\V[HNCVkeURWK=
NCI-H747	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTNwOUSyNlEh\|ryP	NVTmN3lVW0GQR2LFVi=>
MHH-NB-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPJUIpKSzVyPUOuPVU{OTJizszN	MULTRW5IWkWU
MZ1-PC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXRTWM2OD1\|Lkm5NlQh\|ryP	MlrmV2FPT1KHUh?=
MMAC-SF	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z4fWlEPTB;ND6wNlQ3PyEQvF2=	NEXXOmFUSU6JUlXS
NMC-G1	NGDJcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O0XGlEPTB;ND6yNlczOyEQvF2=	M375fnNCVkeURWK=
SW872	NYfOdnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfmdpRKSzVyPUSuN\|Q{PCEQvF2=	M{nRcnNCVkeURWK=
TE-12	NFPae4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CyfWlEPTB;ND61OlM6PCEQvF2=	NVnzd5d1W0GQR2LFVi=>
LU-139	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTRwNkG4N\|Uh\|ryP	M3\VU3NCVkeURWK=
HC-1	M13LPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLZTWM2OD12Lk[5OFk1KM7:TR?=	M4e2dHNCVkeURWK=
COR-L279	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3PGlEPTB;ND63OVg6OSEQvF2=	NFi2VGZUSU6JUlXS
SF268	NIWyRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;zTWM2OD12Lke5PVE3KM7:TR?=	M3e1cnNCVkeURWK=
MC-CAR	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fmfWlEPTB;NT6wOlc2PyEQvF2=	NICzOlJUSU6JUlXS
TK10	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\FenpGUUN3ME21MlM2PDZ7IN88US=>	M4THVnNCVkeURWK=
TE-1	NXTidG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfOPJh6UUN3ME21MlQ6ODB2IN88US=>	MWDTRW5IWkWU
NCI-H2126	NELEOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYezZVRGUUN3ME21MlY1PTd2IN88US=>	MVLTRW5IWkWU
Daudi	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TnUmlEPTB;NT62PVEzKM7:TR?=	NILmOZlUSU6JUlXS
NCI-H1648	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[3NmlEPTB;NT64NVQ2PCEQvF2=	NXH3WYNIW0GQR2LFVi=>
OS-RC-2	NI\scIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:zZZBKSzVyPUWuPVg2QTdizszN	MVrTRW5IWkWU
DJM-1	NF\nU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTZwM{S2OlYh\|ryP	NIjXNWxUSU6JUlXS
LS-1034	NVfYN3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTZwN{W2OkDPxE1?	MkTkV2FPT1KHUh?=
NCI-H1581	NFfHTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Xz[2lEPTB;Nj63PFQxPSEQvF2=	MoH6V2FPT1KHUh?=
UACC-257	NWraeXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\FT2lEPTB;Nz6wOFUyOiEQvF2=	NHLCOYtUSU6JUlXS
KM-H2	NIXtU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe5[oFKSzVyPUeuNVg1PTdizszN	MnLNV2FPT1KHUh?=
NCI-H1436	NE\sPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;HUZd2UUN3ME23MlY6QTN{IN88US=>	NFL6epZUSU6JUlXS
IA-LM	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfLTWM2OD15Lki1PUDPxE1?	MlrEV2FPT1KHUh?=
NCI-H526	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnSzTWM2OD16LkK1OlM4KM7:TR?=	MVzTRW5IWkWU
GCIY	NGn3NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rHOGlEPTB;OD6zOlk3PSEQvF2=	NHjzbppUSU6JUlXS
CP67-MEL	M4jRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu5SYUzUUN3ME24MlU{OjZizszN	NGT3eHVUSU6JUlXS
KALS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W0W2lEPTB;OD64N\|g2OSEQvF2=	M3jqdHNCVkeURWK=
NCI-H1770	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\kRmlEPTB;OD65NFI3PSEQvF2=	NHvtenJUSU6JUlXS
8-MG-BA	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LIZ2lEPTB;OT6zNlg1PCEQvF2=	Mo\LV2FPT1KHUh?=
KY821	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTlwN{e0PFQh\|ryP	MUXTRW5IWkWU
SNB75	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PSSGlEPTB;MUCuNFc3KM7:TR?=	M{\5XHNCVkeURWK=
NCCIT	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfzTWM2OD1zMT6wOVgzKM7:TR?=	MlvMV2FPT1KHUh?=
SJSA-1	M3jBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPOTGhKSzVyPUGxMlI5QTFizszN	MW\TRW5IWkWU
LB373-MEL-D	M17UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTFzLkO4Nlch\|ryP	Mnm2V2FPT1KHUh?=
TALL-1	NIL6TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLPV5prUUN3ME2xNU41ODV6IN88US=>	NYWzW5czW0GQR2LFVi=>
NB69	NFjWfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfWd4RRUUN3ME2xNU44PzB3IN88US=>	MYTTRW5IWkWU
NCI-H1355	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFzLkm0NlYh\|ryP	MYfTRW5IWkWU
DMS-153	NXzhO4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTZ[WpzUUN3ME2xNk4xPDJ4IN88US=>	Mnz3V2FPT1KHUh?=
OPM-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTF{LkG1PVYh\|ryP	NELUfYpUSU6JUlXS
NB1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrPTGNuUUN3ME2xNk4zQSEQvF2=	MlexV2FPT1KHUh?=
A3-KAW	NVfGcI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF{LkOyN\|Yh\|ryP	Mn32V2FPT1KHUh?=
NCI-H1882	NHznfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mom3TWM2OD1zMj60NFY3KM7:TR?=	M1jUdHNCVkeURWK=
KG-1	M1fh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPrfmpKSzVyPUGyMlY2PDVizszN	MoLCV2FPT1KHUh?=
LC4-1	NGDSPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkThTWM2OD1zMj63O\|A3KM7:TR?=	NYfnXoNzW0GQR2LFVi=>
HCE-T	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3FbndrUUN3ME2xN{4xODR7IN88US=>	MV;TRW5IWkWU
NEC8	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrobG1KSzVyPUGzMlExOzhizszN	NFftVWtUSU6JUlXS
IST-MEL1	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLsTWM2OD1zMz61O\|g5KM7:TR?=	NF71dI9USU6JUlXS
EW-3	NV2xSW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEn5XpNKSzVyPUGzMlc1ODJizszN	M2fB[3NCVkeURWK=
CTB-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli3TWM2OD1zND6wN\|I6KM7:TR?=	NFnPXppUSU6JUlXS
LS-123	NXHhfpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{W2SGlEPTB;MUSuNVU5QCEQvF2=	M1jLdHNCVkeURWK=
NCI-H1417	M4TBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF2LkOwOVIh\|ryP	NHq0VY5USU6JUlXS
MZ7-mel	M4XSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fCUmlEPTB;MUSuOFQ{OyEQvF2=	MkjIV2FPT1KHUh?=
JiyoyeP-2003	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrVTWM2OD1zNT62N\|I3KM7:TR?=	M2XQU3NCVkeURWK=
ES6	NIGxSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfMTWM2OD1zNj6yN\|YyKM7:TR?=	MX7TRW5IWkWU
HH	NH;OelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLOTWM2OD1zNz6xPVY{KM7:TR?=	NUTKblFpW0GQR2LFVi=>
SF539	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7TSGFKSzVyPUG3Mlk6OjJizszN	MWjTRW5IWkWU
Calu-6	NXn4c3pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[5eXpNUUN3ME2xPU4zOzlizszN	NXrXc2hwW0GQR2LFVi=>
SK-MM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljTTWM2OD1zOT61OVUh\|ryP	M2[wcnNCVkeURWK=
IST-MES1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vNcmlEPTB;MUmuOlY3OyEQvF2=	NFzBS2dUSU6JUlXS
GI-ME-N	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF7LkiyNlch\|ryP	NUT0R5R7W0GQR2LFVi=>
CAL-148	NX[xeZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37qOWlEPTB;MkCuPVk{PCEQvF2=	MoDLV2FPT1KHUh?=
EVSA-T	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJzLkG0PVkh\|ryP	Mni1V2FPT1KHUh?=
LP-1	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PHWGlEPTB;MkGuN\|Q{OiEQvF2=	M{XPeXNCVkeURWK=
BOKU	NWDEVWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LCN2lEPTB;MkGuOFU{OyEQvF2=	NHfWN5RUSU6JUlXS
KLE	NInxb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrjTWM2OD1{Mj6xPVA{KM7:TR?=	NG\xcIpUSU6JUlXS
LB831-BLC	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJ3LkG1NlYh\|ryP	MYPTRW5IWkWU
NCI-H889	NGDsfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rvRmlEPTB;MkWuNVk{OSEQvF2=	MV;TRW5IWkWU
REH	NFvhOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLyNYhKSzVyPUK1MlQ3PzFizszN	NXP3cG9uW0GQR2LFVi=>
KP-N-RT-BM-1	NF;PSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXETWM2OD1{NT60O\|UzKM7:TR?=	NUGwOHFtW0GQR2LFVi=>
MPP-89	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3CWXhKSzVyPUK1MlU{OTRizszN	NGW3cI5USU6JUlXS
no-11	NYjNOnBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jWfWlEPTB;MkWuO\|Q4KM7:TR?=	MWTTRW5IWkWU
NCI-H748	M4i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrZW25KSzVyPUK1Mlc3OjdizszN	M4fEc3NCVkeURWK=
LB2518-MEL	NGGxV\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HYWWlEPTB;MkeuNVc4OyEQvF2=	M1\xWHNCVkeURWK=
TGBC1TKB	NIjMUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7PUnBKSzVyPUK3MlU2QDVizszN	M{PX[3NCVkeURWK=
MHH-PREB-1	M2LKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3jc3V3UUN3ME2yPE4xPzN2IN88US=>	Mlv1V2FPT1KHUh?=
MZ2-MEL	M4jDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojNTWM2OD1{OD62NVQ{KM7:TR?=	MonDV2FPT1KHUh?=
U-266	NFvNO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLiTJNKSzVyPUK4MlY{PjZizszN	MVzTRW5IWkWU
SNU-C1	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fZe2lEPTB;MkiuPVQ{KM7:TR?=	MYLTRW5IWkWU
SW962	NFP6U\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz5N5dKSzVyPUOwMlI4PDdizszN	NF\Ne\|FUSU6JUlXS
Raji	NFmxcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTNyLkW1PVIh\|ryP	M3z4OnNCVkeURWK=
KNS-42	NH;2VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rtOWlEPTB;M{CuPFk2PiEQvF2=	NFfONGxUSU6JUlXS
LB996-RCC	NX31fGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHjRYdKSzVyPUOxMlE4ODJizszN	NXW4flR[W0GQR2LFVi=>
CHP-126	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[5epJoUUN3ME2zNU4yQTh2IN88US=>	MlHPV2FPT1KHUh?=
RXF393	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnFV4sxUUN3ME2zNk41QTdizszN	MY\TRW5IWkWU
COLO-684	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTN{Lk[0N\|gh\|ryP	M13LTHNCVkeURWK=
A704	NIHVfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX36S3h6UUN3ME2zN{42PTN6IN88US=>	MmDiV2FPT1KHUh?=
A253	M{PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLIWZFKSzVyPUOzMlU5PTJizszN	MnvRV2FPT1KHUh?=
KNS-81-FD	NHzYfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDDdVNKSzVyPUO0MlU1PTZizszN	Mm\wV2FPT1KHUh?=
TE-441-T	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj3c2xKSzVyPUO0MlY{PzFizszN	MXTTRW5IWkWU
HCC2157	M2rOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTN3LkS2NVkh\|ryP	NFHlbnZUSU6JUlXS
ES3	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\VeGlEPTB;M{[uOlc2KM7:TR?=	NFexNGVUSU6JUlXS
NCI-H1155	NEPFU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\xVGlEPTB;M{euPFE2KM7:TR?=	MWDTRW5IWkWU
SNU-C2B	NYTmWXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33QSmlEPTB;M{iuNVY2PCEQvF2=	M4rTR3NCVkeURWK=
JAR	M3O0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn23TWM2OD1\|OD6yOFQ6KM7:TR?=	MXrTRW5IWkWU
GDM-1	M4\0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Hqb2lEPTB;M{iuPVEyPiEQvF2=	M4\1PHNCVkeURWK=
KU812	M1\Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HHfGlEPTB;NEGuOVA4KM7:TR?=	MoTXV2FPT1KHUh?=
BC-1	NFXZWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTR{Lk[3N\|Eh\|ryP	M{LubnNCVkeURWK=
GI-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTR{LkmxPVIh\|ryP	NW\t[VVoW0GQR2LFVi=>
NCI-H1694	NEm3[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTwOIVKSzVyPUS0Mlk1PzJizszN	NG\lNIdUSU6JUlXS
DG-75	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPON3pGUUN3ME20OU4yPTd5IN88US=>	NIHa[FFUSU6JUlXS
COR-L88	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vHTGlEPTB;NEWuNlc4QCEQvF2=	MljDV2FPT1KHUh?=
LS-513	NWT1dG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTR3LkmxOVYh\|ryP	NFX4UlFUSU6JUlXS
HD-MY-Z	NUnLTVl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;WTWM2OD12Nj60OlEzKM7:TR?=	MVjTRW5IWkWU
L-363	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\BTWM2OD12Nj64PFEh\|ryP	MkPuV2FPT1KHUh?=
TE-6	NEnncY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHDTWM2OD12OD60OFYh\|ryP	MUfTRW5IWkWU
NCI-H345	NVniWWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn6yTWM2OD12OD60Olgh\|ryP	M1uwO3NCVkeURWK=
TE-5	M162Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzwXlBIUUN3ME20PU44OTF6IN88US=>	NXKxNJV7W0GQR2LFVi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	- Collapse Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	- Collapse Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Formulation: 50% PEG300 in 50 mM phosphate buffer Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- Collapse

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA|AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 61 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 61 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)